GSK swears off commercial CME providers

Share this article:

GlaxoSmithKline is cutting off commercial CME providers, following Pfizer's lead.

GSK said starting next year, it will fund only “independent” CME programs designed to close gaps in patient care, and that effective immediately, it will no longer fund CME executed by commercial providers, including medical education and communication companies.

“GSK will not support as many medical education programs, but we will continue funding those with the greatest potential to improve patient health,” said GSK president, North America Deirdre Connelly in a statement.

The company will invite grant applications from a pool of around potential grant applicants limited to academic medical centers and affiliated teaching and patient care institutions as well as national medical societies and professional groups.

Pfizer announced a similar policy in 2008.

Publishing and education companies received $463 million in commercial support in 2008 – about 44% of the $1 billion doled out that year, according to data from the Accreditation Council for Continuing Medical Education. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.